New report questions Watson’s cancer treatment recommendations

Watson, IBM’s highly touted artificial intelligence (AI) platform, might not be ready to make its rounds, according to an investigative report from STAT. The news outlet reviewed internal IBM documents that showed Watson often recommended unsafe treatment advice and incorrect recommendations, all while IBM was promoting the AI product to healthcare providers.

The incidents mentioned in the IBM documents happened in 2016, with incomplete training cited as the reason for the shortcomings. According to the STAT report, IBM researchers and physicians at the Memorial Sloan Kettering Cancer Center trained the AI software with hypothetical cases, instead of situations with real patient data.

IBM responded to the STAT report by claiming it presented an out-of-date snapshot of Watson.

“Today, Watson for Oncology is trained to help oncologists treat 13 cancers,” IBM said in a statement. “Our oncology and genomics offerings are used by 230 hospitals around the world and have supported care for more than 84,000 patients, which is almost double the number of patients as of the end of 2017. … We have learned and improved Watson Health based on continuous feedback from clients, new scientific evidence and new cancers and treatment alternatives. This includes 11 software releases for even better functionality during the past year, including national guidelines for cancers ranging from colon to liver cancer.”

This isn’t the first time questions have been raised about the performance of IBM’s AI platform. Reports arose in September 2017 that Watson struggled with interoperability and data collection—problems that can be found in most health IT products.

But critics argued IBM was aiming too high—setting sights on curing cancer rather than improving treatment and diagnosis.

""
Nicholas Leider, Managing Editor

Nicholas joined TriMed in 2016 as the managing editor of the Chicago office. After receiving his master’s from Roosevelt University, he worked in various writing/editing roles for magazines ranging in topic from billiards to metallurgy. Currently on Chicago’s north side, Nicholas keeps busy by running, reading and talking to his two cats.

Around the web

Compensation for heart specialists continues to climb. What does this say about cardiology as a whole? Could private equity's rising influence bring about change? We spoke to MedAxiom CEO Jerry Blackwell, MD, MBA, a veteran cardiologist himself, to learn more.

The American College of Cardiology has shared its perspective on new CMS payment policies, highlighting revenue concerns while providing key details for cardiologists and other cardiology professionals. 

As debate simmers over how best to regulate AI, experts continue to offer guidance on where to start, how to proceed and what to emphasize. A new resource models its recommendations on what its authors call the “SETO Loop.”